Table 2 Baseline characteristics for diabetic or non-diabetic patients with different NLR levels
Variables | NLR-L/Non-T2DM (N = 3656) | NLR-H/Non-T2DM (N = 1139) | NLR-L/T2DM (N = 3063) | NLR-H/T2DM (N = 977) | P Value |
|---|---|---|---|---|---|
Baseline characteristics | |||||
Age, years | 57.09 ± 10.29 | 58.77 ± 10.43 | 59.03 ± 9.71 | 60.74 ± 10.36 | < 0.001 |
Male | 2843 (77.8) | 955 (83.8) | 2234 (72.9) | 773 (79.1) | < 0.001 |
BMI, kg/m2 | 25.70 ± 3.15 | 25.36 ± 3.29 | 26.37 ± 3.19 | 26.01 ± 3.13 | < 0.001 |
Hypertension | 2182 (59.7) | 740 (65.0) | 2074 (67.7) | 716 (73.3) | < 0.001 |
Dyslipidemia | 2325 (63.6) | 709 (62.2) | 2172 (70.9) | 706 (72.3) | < 0.001 |
Smoking history | 2125 (58.1) | 678 (59.5) | 1684 (55.0) | 568 (58.1) | 0.016 |
Previous MI | 649 (17.8) | 207 (18.2) | 611 (19.9) | 211 (21.6) | 0.016 |
Previous PCI | 741 (20.3) | 220 (19.3) | 773 (25.2) | 294 (30.1) | < 0.001 |
Previous CABG | 111 (3.0) | 48 (4.2) | 150 (4.9) | 43 (4.4) | 0.001 |
Previous stroke | 312 (8.5) | 113 (9.9) | 372 (12.1) | 130 (13.3) | < 0.001 |
Previous PAD | 233 (6.4) | 75 (6.6) | 255 (8.3) | 91 (9.3) | 0.001 |
Clinical presentation | < 0.001 | ||||
SAP | 1478 (40.4) | 430 (37.8) | 1356 (44.3) | 355 (36.3) | |
ACS | 2178 (59.6) | 709 (62.2) | 1707 (55.7) | 622 (63.7) | |
Laboratory tests | |||||
Neutrophils, *109/L | 3.74 ± 1.11 | 5.33 ± 1.59 | 3.94 ± 1.14 | 6.02 ± 2.23 | < 0.001 |
Lymphocyte, *109/L | 2.05 ± 0.57 | 1.42 ± 0.42 | 2.17 ± 0.65 | 1.48 ± 0.45 | < 0.001 |
NLR | 1.89 ± 0.51 | 3.95 ± 1.70 | 1.89 ± 0.50 | 4.47 ± 2.87 | < 0.001 |
FBG, mmol/L | 5.13 ± 0.56 | 5.24 ± 0.61 | 7.47 ± 2.56 | 8.02 ± 3.15 | < 0.001 |
HbA1c, % | 5.88 ± 0.33 | 5.87 ± 0.33 | 7.53 ± 1.32 | 7.40 ± 1.50 | < 0.001 |
TG, mmol/L | 1.70 ± 0.93 | 1.63 ± 0.92 | 1.93 ± 1.25 | 1.77 ± 1.13 | < 0.001 |
TC, mmol/L | 4.22 ± 1.05 | 4.10 ± 0.99 | 4.24 ± 1.10 | 4.13 ± 1.08 | 0.001 |
HDL-C, mmol/L | 1.06 ± 0.30 | 1.07 ± 0.32 | 1.02 ± 0.28 | 1.02 ± 0.29 | < 0.001 |
LDL-C, mmol/L | 2.52 ± 0.91 | 2.40 ± 0.86 | 2.52 ± 0.91 | 2.42 ± 0.90 | < 0.001 |
hsCRP, mg/L | 2.47 ± 3.02 | 3.82 ± 4.33 | 2.96 ± 3.37 | 4.39 ± 4.70 | < 0.001 |
Creatinine, μmol/L | 74.37 ± 14.02 | 77.41 ± 15.67 | 74.15 ± 15.47 | 79.44 ± 19.04 | < 0.001 |
eGFR, mL/min/1.73 m2 | 104.20 ± 20.56 | 100.70 ± 21.79 | 103.72 ± 23.08 | 97.45 ± 23.85 | < 0.001 |
LVEF, % | 63.55 ± 6.86 | 63.18 ± 7.09 | 62.99 ± 6.87 | 61.48 ± 8.02 | < 0.001 |
Medications | |||||
DAPT | 3558 (97.3) | 1113 (97.7) | 3008 (98.2) | 957 (98.0) | 0.105 |
β-blocker | 3234 (88.5) | 1007 (88.4) | 2827 (92.3) | 887 (90.8) | < 0.001 |
CCB | 1734 (47.4) | 574 (50.4) | 1546 (50.5) | 499 (51.1) | 0.035 |
Statins | 3534 (96.7) | 1097 (96.3) | 2932 (95.7) | 921 (94.3) | 0.005 |
Nitrate | 3580 (97.9) | 1122 (98.5) | 2997 (97.8) | 949 (97.1) | 0.184 |
Coronary procedural data | |||||
LM/three-vessel disease | 1449 (39.6) | 465 (40.8) | 1509 (49.3) | 518 (53.0) | < 0.001 |
Chronic total occlusion | 293 (8.0) | 95 (8.3) | 249 (8.1) | 89 (9.1) | 0.733 |
Bifurcation lesions | 748 (20.5) | 224 (19.7) | 601 (19.6) | 212 (21.7) | 0.503 |
Moderate to severe calcification | 578 (15.8) | 205 (18.0) | 577 (18.8) | 200 (20.5) | 0.001 |
Number of treated vessels | 1.41 (0.64) | 1.38 (0.63) | 1.45 (0.70) | 1.52 (0.76) | < 0.001 |
Number of stents | 1.88 ± 1.03 | 1.87 ± 1.01 | 1.97 ± 1.09 | 2.04 ± 1.09 | < 0.001 |
IABP | 13 (0.4) | 9 (0.8) | 46 (1.5) | 16 (1.6) | < 0.001 |
SYNTAX score | 11.25 ± 7.32 | 12.07 ± 7.75 | 12.24 ± 7.78 | 13.16 ± 8.22 | < 0.001 |